Home | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services

Close Ad ☒

Show Ad

Extreme Language Ultra-High Potency
The newest generation of small-molecule therapies bring containment needs well beyond those of conventional HPAPIs. What does this mean for the pharma lexicon – and the pharma landscape? read more
An Interview With Kim Boericke
Veristat’s new CEO, Kim McLean Boericke, is one step closer to changing the tide in representing the small fraction of companies led by women and is now the only female with the highest job among the top-8 clinical research organizations (CROs). read more
Material-Sparing Strategies for Rapid Development and Scale-Up of Complex Drug Products
In an industry where complex molecules and first-in-human (FIH) formulations often come with very limited API supply, material-sparing strategies are central to efficient CMC development. read more
An interview with Franco Negron
In this interview, we spoke with Franco Negron, CEO of Simtra, about how the company is advancing its position as a premier CDMO for sterile injectables while preparing for the next wave of complex biologics. read more

Clinical Trials - Transforming Drug Development
Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs Watch Now

Orphan Therapeutics Accelerator Adds CDMO and Access Partners to Ultra-Rare Disease Network
Thursday, June 25, 2026
Orphan Therapeutics Accelerator has expanded its Orphan ClinDevNet development network with four new strategic partners—OPIS, Uniphar, SK pharmteco ... read more
Celerion Expands Zurich Bioanalytical Laboratory
Thursday, June 25, 2026
Celerion announced the expansion of its bioanalytical laboratory in Zurich, Switzerland. The investment strengthens Celerion’s ability to support ... read more
Shilpa Biologicals Commissions Integrated ADC Drug Substance GMP Manufacturing Facility
Thursday, June 25, 2026
Shilpa Biologicals announced the commissioning of a state-of-the-art Antibody–Drug Conjugate (ADC) GMP manufacturing facility, purpose-built and ... read more
WuXi Biologics’ 25th Drug Substance Plant Completes First GMP Run with No Deviations
Thursday, June 25, 2026
WuXi Biologics said its MFG17 drug substance facility at the Shanghai Fengxian site has successfully completed its first GMP production campaign, with... read more
Sanner Unifies Global Operations Under Single Brand
Tuesday, June 23, 2026
Sanner is rebranding its subsidiaries under a single Sanner Group umbrella, beginning with the transition of UK-based Springboard to Sanner UK. read more